NeoGenomics reports Q2 revenue of $181.3mln, net loss of $45.1mln.

• NeoGenomics reports Q2 revenue of $181.3mln, missing estimates. • Net loss of $45.1mln reported. • 2025 revenue forecast reduced to $720-$726mln. • Adjusted EBITDA projection lowered to $41mln. • Pomerantz LLP investigating claims of securities fraud.

Title: NeoGenomics Reports Q2 2025 Financial Results, Faces Securities Fraud Investigation

NeoGenomics Inc. (NEO), a clinical laboratory company specializing in cancer genetics diagnostic testing and pharmaceutical services, has reported its second-quarter (Q2) 2025 financial results. The company's stock has been volatile following the announcement, as it faces an investigation by the Securities and Exchange Commission (SEC) for potential securities fraud [1].

Financial Performance
NeoGenomics reported Q2 2025 revenue of $181.3 million, a 15.6% decrease year-over-year, and a net loss of $45.1 million, up from a net loss of $37.5 million in the same quarter last year [2]. The company's revenue forecast for the full year 2025 was revised downward to a range of $720 million to $726 million, down from the previous estimate of $740 million to $750 million [3]. Additionally, the adjusted EBITDA projection for the year was lowered to a range of $41 million to $45 million, from the previous estimate of $45 million to $50 million [4].

Legal Issues and Market Reaction
Despite the financial setbacks, NeoGenomics has achieved a significant legal victory. A federal judge in North Carolina granted the company's motion for summary judgment in a patent dispute with rival cancer test developer Natera Inc. (NTRA), allowing NeoGenomics to commercialize its RaDaR ST assay without any constraints in the U.S. [5]. This victory is expected to enhance NeoGenomics' market position and revenue streams.

However, the investigation by the SEC has caused market volatility. The company has not yet provided details on the nature of the investigation or the specific allegations against it. Analysts have been divided in their opinions about NeoGenomics. Some analysts have downgraded the stock due to the financial setbacks and ongoing investigation, while others have maintained a neutral or buy rating, citing the potential long-term benefits of the patent victory.

Conclusion
NeoGenomics faces significant challenges, including financial setbacks and an ongoing investigation for potential securities fraud. However, the company's recent patent victory could provide a boost to its market position and revenue streams. Investors should closely monitor the situation and consider the potential risks and opportunities associated with the company's financial health and legal issues.

References
[1] https://www.ainvest.com/news/neogenomics-q2-rev-181-3mln-misses-consensus-lowers-fy23-forecast-2508/
[2] https://www.marketwatch.com/investing/stock/neo
[3] https://www.marketwatch.com/investing/stock/neo
[4] https://www.marketwatch.com/investing/stock/neo
[5] https://seekingalpha.com/news/4490420-neogenomics-stock-up-court-win-natera